-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Paul Kleutz
-
Paul G. Kluetz, MD
Posted: June 24, 2020 Paul G. Kluetz, MD, has been named the FDA’s new Deputy Director of the OCE. During his 10 years with the FDA, Dr. Kluetz founded the OCE’s Patient-Focused Drug Development program. The IASLC looks forward to our continued collaboration and partnership with the FDA with regard to lung cancer therapies, diagnostics,…